---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002691"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:59:55.576590+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Regeneron expects Q4 IPR&D charge of ~$19M and $60M matching donation charge

## Summary
- Expects ~$19M pre-tax IPR&D charge in Q4 2025, reducing GAAP and non-GAAP diluted EPS by ~$0.14.
- Records ~$60M SG&A charge for matching donations to Good Days retinal fund in Q4 2025.
- Preliminary Q4 and FY2025 financial update provided at J.P. Morgan Healthcare Conference.

## SEC filing metadata
- accession: 0001104659-26-002691
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465926002691/0001104659-26-002691-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465926002691/tm262861d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002691
- JSON: https://secwatch.observer/filing/0001104659-26-002691.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002691.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.